CM Naidu woos investors in Singapore, Eversendai proposes mega fabrication unit in AP
In a meeting with representatives of Surbana Jurong (SJ), a leading global urban infrastructure company, Naidu extended an invitation to participate in Andhra Pradesh's ambitious 'Housing for All' programme.
He highlighted the State's focus on large-scale infrastructure projects, including the development of 20 ports and 15 airports, positioning Andhra Pradesh as an emerging logistics hub. He also shared plans to transform key areas into industrial townships.
Surbana Jurong expressed keen interest in contributing to the State's housing and infrastructure development, signalling potential collaboration in these sectors.
Naidu also met Tan Sri AK Nathan, Chairman and Managing Director of Malaysia-based Eversendai Corporation Berhad. The discussions centred on establishing a state-of-the-art fabrication factory, and an integrated training centre in Andhra Pradesh.
Eversendai proposes 2L sq mt facility
Eversendai has proposed setting up of the facility in approximately 2,00,000 square metres, strategically located to enable the transportation of fabrication equipment across India. The initiative is expected to drive industrial growth, and create significant employment opportunities in the State.
Eversendai also evinced interest in participating in infrastructure projects for the development of Amaravati Capital City. Additionally, the company discussed collaboration with institutions like IIT Tirupati and IIIT Sri City to establish a structural engineering training centre.
Eversendai highlighted its global expertise, having contributed to iconic projects such as the Burj Khalifa, and Statue of Unity in Gujarat.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
2 minutes ago
- Business Standard
ECB aims for IPL-like success as Indian groups invest in The Hundred
The investment of four IPL owners into The Hundred will enable the England and Wales Cricket Board-backed event to grow rapidly and learn immensely from the skills possessed by the top minds working for the world's biggest T20 league. Out of the eight teams in the 100-ball competition, four will be partially owned by owners of Mumbai Indians, Sunrisers Hyderabad, Lucknow Super Giants and Delhi Capitals (only GMR group involved). After a long delay, the ECB finalised the deals with the IPL and other investors on Wednesday. Reliance Group, which will own 49 percent of the London-based Oval franchise, and Trent Rockets are yet to close agreements with the ECB. "It's brilliant. You look at what the IPL has done, forget cricket, in sport in general, the growth it's achieved in 18 short years. It's nothing short of phenomenal," said Vikram Banerji, Managing Director of The Hundred, in response to a PTI query on Thursday. "So the growth and the learnings, both on the field and off the field, that they can bring into this tournament, with the balance of the other investors that we've got from America and wherever else, I'm really excited about that side of things, about the skill sets that are now coming into English cricket," he said. The deal will take effect from 2026 season and the investors will take operation control of the franchise from October 1, 2025. Asked about the reason for the delay in closing the agreement with the Reliance-backed Oval franchise and Trent Rockets, Banerji said: "Right at the start we offered all the investors the opportunity to sign and close immediately whenever the legals were all done and have some involvement in this year. "On the whole, it's been run as it was, or close formally at the end of the season, early October, when they close formally, when they take operational control of the name of the brand. So those two chose that months ago. "With Trent Rockets, it's documents were signed and all the rest of it fully there. With the Oval Invincibles, there's three things left on their venue hire stuff that they're working through. They're small things, it'll be a matter of weeks, and that'll get signed out." Banerji and the rest of the stakeholders will soon have a meeting with the new investors for the tournament operations from 2026 onwards. Barring The Hundred, all leagues including the IPL are being played in the T20 format. Is there an inclination from the IPL owners to switch to the standard T20 format from the current 100-ball a side format? "I think you have to look at what works in this country. There have been some discussions around kind of it works elsewhere, but in this country, the format has provided us with some really interesting things, especially from a broadcast perspective in terms of the reach it's provided and that ability to create a new crowd. "At the moment, it's the 100 format, and that will remain for now. But let's see where we get to in a month," said Banerji, who added the participation of active Indian players remains off the card despite the IPL investment into the competition. Sitting alongside Banerji, ECB chief executive Richard Gould, was also asked about the participation of Pakistan players in The Hundred in light of Indian investment. No Pakistan player was picked in the 2025 draft for different reasons. Gould asserted the ECB will take action if the owners are found to be discriminatory in player selection irrespective of his nationality. "We would expect players of all nations to be selected for all teams. I haven't had the need to have any discussion at this point (with new investors)." So is the latest draft just a coincidence? "I don't, I don't know. But we have not had any discussions with the owners at this point. But, we've got very clear anti-discrimination policies within cricket in England. And if those are, if those are not adhered to, our cricket regulator will take action," said Gould. Now that the deals are done, the ECB expects the change in name of at least three teams backed by IPL team owners including Reliance, RPSG and GMR. The sale of stakes have catapulted the valuation of teams to over 975 million pounds with more than 500 million pounds set to be invested in English cricket.
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
Mankind Pharma Q1 PAT drops 17.4% despite 24% revenue growth, costs surge
Delhi-based pharmaceutical major Mankind Pharma reported a 17.4 per cent year-on-year (YoY) decline in consolidated profit after tax (PAT) for the first quarter of FY2025–26 (Q1 FY26), at Rs 445 crore, down from Rs 538 crore in the same quarter last year. The company attributed the fall in profitability to a rise in raw material costs, higher component consumption, and increased employee expenses. Despite the PAT decline, revenue from operations grew significantly—by 24 per cent YoY—to Rs 3,570 crore from Rs 2,867 crore in Q1 FY25. At the operating level, earnings before interest, tax, depreciation, and amortisation (EBITDA) rose to Rs 850 crore in the quarter under review, compared to Rs 675 crore a year ago. The adjusted EBITDA margin improved slightly to 23.8 per cent from 23.6 per cent in the corresponding period last year. Rajeev Juneja, vice chairman and managing director of Mankind Pharma, said the growth in revenue and margins was driven by strong performance in the chronic and consumer healthcare segments, and by the consolidation of Bharat Serums and Vaccines (BSV), acquired in October 2024 for Rs 13,768 crore. A key drag on the bottom line was finance costs, which rose sharply to Rs 170.65 crore in Q1FY26—17 times higher than Rs 10.84 crore in Q1FY25—largely due to financing related to the BSV acquisition. Mankind Pharma said its chronic therapies business outperformed the Indian Pharma Market (IPM) by 1.4x, with cardiac and antidiabetics segments growing 1.5x and 1.6x faster, respectively. Domestic business revenue rose 18.9 per cent YoY to Rs 3,101 crore. The consumer healthcare segment posted a 15 per cent increase in revenue, led by consistent secondary sales growth for key brands such as Manforce condoms and Gas-O-Fast. The company's exports segment recorded a strong 81 per cent YoY growth, supported by a ramp-up in base business and integration of BSV's global operations. Mankind Pharma announced its results post-market hours. Its stock closed marginally lower by 0.28 per cent at Rs 2,567.75 per share on the Bombay Stock Exchange (BSE) on Thursday. The company remains optimistic about sustaining momentum in both chronic therapies and consumer brands, while continuing to integrate BSV's operations for long-term value creation.
&w=3840&q=100)
Business Standard
2 minutes ago
- Business Standard
Microsoft goes past $4 trillion m-cap, second to achieve feat after Nvidia
On Wednesday, the tech giant posted the annual revenue of $75 billion for the first quarter of the financial year 2026 (January-March) for its flagship cloud computing platform-Azure New Delhi Microsoft on Thursday became the second company - after Nvidia - to go past $4 trillion mark in market valuation. The milestone came after the Redmond-based tech giant posted quarterly earnings that beat Wall Street's expectations. On Wednesday, Microsoft posted annual revenue of $75 billion for the first quarter of the financial year 2026 (January-March), up 34 per cent, for its flagship cloud computing platform-Azure. The first company to cross the $4 trillion mark was chip giant Nvidia in July 2025. Shares of Microsoft were up 6.6% at $546.33 in morning trading.
